(Last Updated On: October 30, 2018)

Authors: Stephanie T. de Leon, MD and Ma. Jasmin J. Jamora, MD, FPDS

Abstract

Introduction: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. Despite this, much is unknown about the initial triggers of the disease. Gliptins, a newly introduced oral medication for type 2 diabetes mellitus (T2DM) has been recently recognized as a potent trigger of bullous pemphigoid.

Case summary: A 75-year old Filipino female presented with a 2-month history of pruritic tense bullae which started on the lower extremities and later on became generalized. She had absent mucosal lesions. She had a history of hypertension, cerebrovascular disease and a recent diagnosis of type 2 diabetes mellitus. She was started on Linagliptin 4 months prior to the onset of the tense blisters. Clinical findings were confirmed by histopathologic and direct immunofluorescence studies.

Conclusion: The population mostly affected by BP is the elderly, who oftentimes exhibit co-morbid diseases. Awareness of factors, like medications and diseases significantly associated with BP is therefore warranted in the effective and long-term management of this blistering disease.

 

Citation

 

Keywords

bullous pemphigoid, linagliptin, gliptin

More Articles

A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions

  Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS     Abstract Background: Virgin coconut oil (VCO) has been reported...

read more